Skip to ContentSkip to Navigation
About us Practical matters How to find us dr. A.J. van der Wekken


Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer

In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non–small-cell Lung Cancer

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands

95P Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments

Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations

Amivantamab Compared with Real-World Physician’s Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Read more


Effect van pil tegen longkanker

Pil tegen longkanker 'halveert kans op overlijden' voor kleine groep patiënten

Hoop voor kleine groep longkankerpatiënten: pil per dag halveert kans op overlijden

Doelgerichte therapie bij longkanker

Actionabiliteit van on-target ALK-resistentiemutaties in niet-kleincellig longcarcinoom

Longkanker: welke vorm heb ik?

Plasma testing

Longkanker in Perspectief

Oncologie longkanker special

Magazine Longkanker

Read more